CCMH
ACHN

Cornerstone Capital Management Holdings’s Achillion Pharmaceuticals ACHN Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$278K Buy
97,088
+5,000
+5% +$18.2K ﹤0.01% 1080
2017
Q3 		$413K Buy
92,088
+2,900
+3% +$12.9K ﹤0.01% 1077
2017
Q2 		$408K Sell
89,188
-27,570
-24% -$111K ﹤0.01% 1064
2017
Q1 		$490K Buy
+116,758
New +$485K ﹤0.01% 1064
2016
Q4 		– Sell
-13,531
Closed -$108K – 1463
2016
Q3 		$108K Buy
13,531
+9,270
+218% +$78.8K ﹤0.01% 1250
2016
Q2 		$33K Buy
4,261
+3,600
+545% +$30.9K ﹤0.01% 1337
2016
Q1 		$5K Sell
661
-20,370
-97% -$149K ﹤0.01% 1477
2015
Q4 		$227K Sell
21,031
-269
-1% -$2.44K ﹤0.01% 1190
2015
Q3 		$147K Hold
21,300
– – ﹤0.01% 1274
2015
Q2 		$189K Buy
21,300
+1,300
+7% +$12.3K ﹤0.01% 1206
2015
Q1 		$197K Buy
20,000
+2,100
+12% +$26.2K ﹤0.01% 1183
2014
Q4 		$219K Buy
17,900
+500
+3% +$6.11K ﹤0.01% 1084
2014
Q3 		$174K Buy
+17,400
New +$162K ﹤0.01% 1120

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cornerstone Capital Management Holdings's ACHN Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Achillion Pharmaceuticals (ACHN) stake by 5.4% in Q4 2017, buying an estimated $18.2K and bringing the position to 97,088 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1080.

Cornerstone Capital Management Holdings first reported a position in ACHN in Q3 2014 and has held it in 13 quarters since. The position peaked at $490K in Q1 2017. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Cornerstone Capital Management Holdings held 97,088 shares of Achillion Pharmaceuticals worth $278K as of Q4 2017.
  • Cornerstone Capital Management Holdings bought 5,000 Achillion Pharmaceuticals shares in Q4 2017, an estimated $18.2K.
  • Achillion Pharmaceuticals made up ﹤0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #1080 holding.
  • Cornerstone Capital Management Holdings first reported a position in Achillion Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
  • Cornerstone Capital Management Holdings's Achillion Pharmaceuticals position peaked at $490K in Q1 2017.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.